alexa The Clinical Pharmacists Main Focus | OMICS International
ISSN: 1920-4159
Journal of Applied Pharmacy

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Clinical Pharmacists Main Focus

Mauro Luisetto1*, Behzad Nili-Ahmadabadi2 and Ghulam Rasool Mashori3

1Applied Pharmacologist, European Specialist in Laboratory Medicine, Italy

2Nano Drug Delivery, Chapel Hill, NC, USA

3Peoples University of Medcial and Health Sciences for Woman, Nawabshah, Pakistan

*Corresponding Author:
Luisetto M
Pharmacologist, European Specialist in Laboratory Medicine
Hospital Pharmacist’s Manager, Italy
Tel: 3402479620
E-mail: [email protected]

Received date: September 06, 2017; Accepted date: September 08, 2017; Published date: September 15, 2017

Citation: Luisetto M, Nili-Ahmadabadi B, Mashori GR (2017) The Clinical Pharmacists Main Focus. J Appl Pharm 9:e114. doi: 10.21065/1920-4159.1000e114

Copyright: © 2017 Luisetto M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Applied Pharmacy

Introduction

We can see that severe and critical patient condition gives frequently high mortality and morbidity rate and so this condition need the best available rational decision making systems involved in therapy. If we have 40% in mortality rate 4 patient/10 can be involved in exits (We can think also to severe infectious disease, some poisoning, major surgery, end stage renal failure, ICU, trauma, burns patients, transplants But many other conditions with high mortality rate).

In this specific kind of patient a multidisciplinary medical team with added the specific pharmaceutical competencies and knowledge can reduce this rate saving more patient versus equips without this expertise [1-4]. Since from the clinical trial in registration of new molecules the pharmaceutical knowledge can be useful instruments to better evaluate (in the medical team) the real efficacy [5,6] and the real opportunity that this can gives in pharmacological treatment especially for severe conditions.

The single Patient life needs the best bio-medical competencies but also the specific pharmaceutical knowledge at the same time to complete the correct decision making systems in clinician’s treatment.

Discussion and Conclusion

We have seen in scientific bibliography that severe patient condition (or critical), or some kind of patient like transplanted, severe oncologic patients, serious infectious disease, heart failure, relevant cardiovascular conditions et other can have more clinical results when clinical pharmacist is permanent member of the medical team because the pharmaceutical knowledge is added to the biomedical medical expertise.

We have also see that this professionals can not to be applied to all kind of patients (too low the number of clinical pharmacist applied in hospital versus clinicians) and for this reason they must be applied in the really critical and severe patient to use this resource in best way [7,8].

We think that the main focus of the clinical pharmacist must be applied in priority way to the most critical patients in order to achieve the best results available [9]. In this condition even benefit of 1 life achieved in mortality rate is a real golden endpoint (we can think for example to a paediatric poisoning, or severe infectious disease in pregnancy or the effect of inefficacy immunosuppressive therapy in transplanted et other) [10]. This can be considered in example as a reduction in NNT to improve a therapeutic strategy.

The same preventing of diffusion of MDR antimicrobial resistance monitoring the right molecules used can be an efficacy instrument to preserve the efficacy of some parenteral antimicrobials in today pattern of resistances [11]. Since ancient time in many prehistoric cultures the use of remedies available was a fundamental fact in order to survive in dangerous situations and only in recent time’s pharmacy was divided from medicine (about 1200 d.c FEDERICO II of SVEVIA named STUPOR MUNDI).

Before 1200 dc in fact pharmacist and physicians professions where practice by the same physicians and only to prevent some kind of abuse this two professions and arts was divided: to the pharmacist the role in drugs preparation in magisterial formula and providing this remedies to patient under physicians prescription and to the physicians diagnostic and therapeutic exclusive competence.

But observing the literature cited in this paper we can see that today (as well as in past) the clinical outcomes is better obtained adding the pharmaceutical competencies to the clinicians works and this presence is the medical team is request to improve some clinical outcome [2-4,7,12-14].

The clinical pharmacist and medicinal chemists expertise also can add the right pharmaceutical knowledge to improve pharmacokinetics or dynamics of some molecules if request by clinicians or pharmaceutical industries in order to reduce the failure of a pharmacological strategy (using an example chemistry modify in drugs design, new delivery systems to have a better pattern in ADME or other strategy to improve the global dynamics in research and industries level) [15].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 845
  • [From(publication date):
    November-2017 - Sep 20, 2018]
  • Breakdown by view type
  • HTML page views : 786
  • PDF downloads : 59
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

bornova escort

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version